Sutro Biopharma, Inc.

Sutro Biopharma is an oncology company focused on developing site-specific and novel-format antibody drug conjugates (ADCs). Its proprietary platforms include XpressCF, a cell-free protein synthesis platform, and XpressCF+, a site-specific conjugation platform. The lead product candidate is STRO-004, a tissue factor (TF) targeting ADC for treating TF-expressing solid tumors such as non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. Additionally, Sutro is developing STRO-003, an ADC targeting ROR1 for solid tumors like triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. The company also has pneumococcal conjugate vaccine candidates VAX-24 and Vax-31 in Phase II/III trials for invasive pneumococcal disease in adults and infants.

Sutro Biopharma is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol STRO. The stock is traded in US Dollars (USD), as the company is based in the United States. Being listed on a major US exchange provides liquidity and access to a broad investor base. The NasdaqGM is a tier of the Nasdaq Stock Market that lists companies meeting certain financial and corporate governance requirements. Investors can trade STRO shares during regular market hours, and the stock is subject to the same reporting and regulatory standards as other US-listed companies.

Sutro Biopharma operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies using advanced biological processes. The company's work centers on antibody drug conjugates (ADCs) and vaccine candidates, leveraging its proprietary cell-free protein synthesis platform. Biotechnology companies like Sutro are characterized by high research and development spending, long product development cycles, and the potential for significant returns if therapies gain regulatory approval. The Healthcare sector encompasses a wide range of companies, from pharmaceuticals to medical devices, and Sutro's specialization in oncology and infectious disease vaccines places it at the forefront of targeted therapeutic development.

Sutro Biopharma is headquartered in South San Francisco, California, United States. The company primarily serves the US market but has international collaborations. For instance, it has a collaboration and license agreement with Vaxcyte to develop vaccine candidates for infectious diseases. Additionally, Sutro has partnerships with Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China, with Ipsen to develop and commercialize STRO-003 (an ADC targeting ROR1), and with Astellas Pharma Inc. to develop immunostimulatory ADCs. These agreements extend the company's reach into markets such as China and other regions, though its core operations remain in the US. The company was incorporated in 2003 and was formerly known as Fundamental Applied Biology, Inc.

Sutro Biopharma generates revenue primarily through collaboration and license agreements with pharmaceutical partners. The company has entered into multiple strategic partnerships: with Vaxcyte to co-develop pneumococcal vaccine candidates (VAX-24 and Vax-31); with Tasly Biopharmaceuticals for STRO-002 in Greater China; with Ipsen for STRO-003 targeting ROR1; and with Astellas Pharma for immunostimulatory ADCs. These agreements typically involve upfront payments, milestone payments, and royalties on future product sales. Additionally, Sutro may generate revenue from its proprietary platforms, XpressCF and XpressCF+, by licensing them to other companies. As a clinical-stage biotechnology company, Sutro does not yet have any approved products on the market, so its current revenue is derived entirely from these partnerships. The company's lead product candidate, STRO-004, is still in development, and future revenue will depend on successful clinical trials and regulatory approvals.